Asthmatic Clinical Trial
Official title:
A Phase II, Monocentric, Open, Randomized, 6-way Cross-over Clinical Pharmacology Study to Evaluate the Lung Bioavailability of BDP/B17MP and Formoterol and the Total Systemic Exposure Across Two Different Strengths of CHF 1535 NEXThaler Dry Powder Inhaler (Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate 100/6 mcg and 200 mcg) Administered With and Without Activated Charcoal in Adult Asthmatic Patients.
Verified date | October 2021 |
Source | Chiesi Farmaceutici S.p.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is aimed to assess the dose proportional total systemic exposure (when the administration is without the activated charcoal) to B17MP (active metabolite of BDP) and its lung bioavailability (when the administration is with the activated charcoal) after single inhalation of CHF 1535 NEXThaler DPI at two dose strengths. At the same time, the study will assess if the lung deposition and the total systemic exposure to Formoterol is affected by increasing doses of BDP.
Status | Completed |
Enrollment | 30 |
Est. completion date | January 2013 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Diagnosis of asthma as defined by Global Initiative for Asthma (GINA) 2011 - Asthmatic patients already treated with low daily doses of Inhaled Corticosteroids (ICS) (eg budesonide or equivalent lower than 400 mcg/day) or low dose of ICS/Long Acting Beta2 Agonists (LABA) fixed combinations. - Patients with Forced Expiratory Volume in 1 sec (FEV1) >= 70 % of predicted values - Non or ex-smokers - Body Mass Index (BMI) >= 18.5 and <= 32 kg/m2 Exclusion Criteria: - Pregnant or lactating women unless using acceptable methods of contraception - Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) - History of near fatal asthma - Patients with abnormal QTcF at screening Visit - Hospitalization due to asthma exacerbation within 4 weeks prior to the screening visit or during the run-in period. - Lower respiratory tract infection within 4 weeks prior to the screening visit or during the run-in period. - History of drug addiction or excessive use of alcohol ; - Diagnosis of restrictive lung disease. - Patients treated with oral or parenteral corticosteroids in the previous 2 months before the screening visit (3 months for parenteral depot corticosteroids) - Significant medical history or any laboratory abnormality indicative of a significant underlying condition |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Medicine Evaluation Unit | Manchester |
Lead Sponsor | Collaborator |
---|---|
Chiesi Farmaceutici S.p.A. |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Plasma glucose | the following parameters will be evaluated: AUC0-4h, AUC0-12h, Cmax and tmax | from predose until 12 hours postdose | |
Other | Heart rate (HR) | the following parameters will be evaluated: HR AUC0-12/12h | from predose until 12 hours postdose | |
Other | Plasma cortisol | the following parameters will be evaluated: AUC0-24, Cmin and tmin | from predose until 24 hours postdose | |
Other | Plasma potassium | the following parameters will be evaluated: AUC0-4h, AUC0-12h, Cmin ad tmin | from predose until 12 hours postdose | |
Other | Systolic and Diastolic Blood Pressure (SBP and DBP) | the following parameters will be evaluated: SBP AUC0-12/12h and DBP AUC0-12/12h | from predose until 12 hours postdose | |
Primary | Formoterol AUC0-t and B17MP AUC0-t | from predose until 12 hr post dose | ||
Secondary | BDP pharmacokinetic (PK) parameters | The following parameters will be evaluated: AUC0-t, AUC0-12h, AUC0-inf, Cmax, tmax, t1/2 | from predose until 12 hr post dose | |
Secondary | Other PK parameter of B17MP and formoterol | the following pharmacokinetic parameters will be evaluated: AUC0-12, AUCinf, Cmax, tmax, t1/2 | from predose until 12 hours postdose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05904002 -
Effect of Incentive Spirometery on Asthmatic Pregnant Women
|
N/A | |
Completed |
NCT01022931 -
Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva
|
N/A | |
Completed |
NCT02967393 -
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
|
Phase 4 | |
Completed |
NCT06133985 -
Effects of Costovertebral Joint Mobilization on Respiratory Function in Asthmatic Patients
|
N/A | |
Completed |
NCT04650464 -
Cardiopulmonary Fitness in Children With Asthma Versus Healthy Children
|
||
Completed |
NCT04267666 -
Inspiratory Muscle Strength Training and Incentive Spirometer on Postmenopausal Asthmatic Women
|
N/A | |
Completed |
NCT02383069 -
Pulmonary Rehabilitation in Asthmatic Patient
|
N/A | |
Recruiting |
NCT05915845 -
Laura Mitchell's Relaxation Versus Papworth Exercise in Ashmatic Patient
|
N/A | |
Completed |
NCT00836368 -
In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics
|
Phase 1 | |
Completed |
NCT02227394 -
Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients
|
Phase 2 |